Basic Information
RNALocate ID: | RLID:11000860 |
RNA Symbol: | hsa-miR-26a-5p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-26a |
RNA ID: | miRBase:MIMAT0000082 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001347 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001348 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001349 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001350 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001351 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001352 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001353 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001354 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001355 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001356 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000849 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
RLID:11000850 | Exosome | Glioblastoma cells | 19011622 |
RLID:11000851 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11000852 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000853 | Exosome | Brain tissue | 23382797 |
RLID:11000854 | Exosome | Plasma | 23663360 |
RLID:11000855 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000856 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11000857 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
RLID:11000858 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11000859 | Microvesicle | Plasma | 23077538 |
RLID-D:11000018 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
RLID-D:11000281 | Microvesicle | Blood|Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-26a-5p | Idiopathic pulmonary fibrosis | MNDR-E-MI-33070 |
MNDR | hsa-miR-26a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-33071 |
MNDR | hsa-miR-26a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-33072 |
MNDR | hsa-miR-26a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-33073 |
MNDR | hsa-miR-26a-5p | Oral squamous cell carcinoma | MNDR-E-MI-33074 |
MNDR | hsa-miR-26a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-33075 |
MNDR | hsa-miR-26a-5p | Medulloblastoma | MNDR-E-MI-33076 |
MNDR | hsa-miR-26a-5p | B cell lymphoma of malt type | MNDR-E-MI-33077 |
MNDR | hsa-miR-26a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-33078 |
MNDR | hsa-miR-26a-5p | Lymphoma | MNDR-E-MI-33079 |
MNDR | hsa-miR-26a-5p | Lymphoma non-hodgkin | MNDR-E-MI-33080 |
MNDR | hsa-miR-26a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-33081 |
MNDR | hsa-miR-26a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-33082 |
MNDR | hsa-miR-26a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-33083 |
MNDR | hsa-miR-26a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-33084 |
MNDR | hsa-miR-26a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-33085 |
MNDR | hsa-miR-26a-5p | Niemann-pick disease type c | MNDR-E-MI-33086 |
MNDR | hsa-miR-26a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-33087 |
MNDR | hsa-miR-26a-5p | Anaplastic thyroid cancer | MNDR-E-MI-33088 |
MNDR | hsa-miR-26a-5p | Dermatomyositis | MNDR-E-MI-33089 |
MNDR | hsa-miR-26a-5p | Prostate cancer | MNDR-E-MI-33090 |
MNDR | hsa-miR-26a-5p | Gastric cancer | MNDR-E-MI-33091 |
MNDR | hsa-miR-26a-5p | Gastric lymphoma | MNDR-E-MI-33092 |
MNDR | hsa-miR-26a-5p | Alzheimer disease | MNDR-E-MI-33093 |
MNDR | hsa-miR-26a-5p | Intracranial aneurysm | MNDR-E-MI-33094 |
MNDR | hsa-miR-26a-5p | Bladder cancer | MNDR-E-MI-33095 |
MNDR | hsa-miR-26a-5p | Esophageal carcinoma | MNDR-E-MI-33096 |
MNDR | hsa-miR-26a-5p | Dysautonomia familial | MNDR-E-MI-33097 |
MNDR | hsa-miR-26a-5p | Myotonic dystrophy | MNDR-E-MI-33098 |
MNDR | hsa-miR-26a-5p | Duchenne muscular dystrophy | MNDR-E-MI-33099 |
MNDR | hsa-miR-26a-5p | Primary biliary cirrhosis | MNDR-E-MI-33100 |
MNDR | hsa-miR-26a-5p | Graves disease | MNDR-E-MI-33101 |
MNDR | hsa-miR-26a-5p | Leukemia | MNDR-E-MI-33102 |
MNDR | hsa-miR-26a-5p | Cardiovascular disease | MNDR-E-MI-33103 |
MNDR | hsa-miR-26a-5p | Carotid stenosis | MNDR-E-MI-33104 |
MNDR | hsa-miR-26a-5p | Moyamoya disease | MNDR-E-MI-33105 |
MNDR | hsa-miR-26a-5p | Lung cancer | MNDR-E-MI-33106 |
MNDR | hsa-miR-26a-5p | Down syndrome | MNDR-E-MI-33107 |
MNDR | hsa-miR-26a-5p | Parkinson disease | MNDR-E-MI-33108 |
MNDR | hsa-miR-26a-5p | Niemann-pick disease | MNDR-E-MI-33109 |
MNDR | hsa-miR-26a-5p | Breast cancer | MNDR-E-MI-33110 |
MNDR | hsa-miR-26a-5p | Thyroid cancer | MNDR-E-MI-33111 |
MNDR | hsa-miR-26a-5p | Pituitary neoplasms | MNDR-E-MI-33112 |
MNDR | hsa-miR-26a-5p | Pancreatic cancer | MNDR-E-MI-33113 |
MNDR | hsa-miR-26a-5p | Melanoma | MNDR-E-MI-33114 |
MNDR | hsa-miR-26a-5p | Rectum adenocarcinoma | MNDR-E-MI-33115 |
MNDR | hsa-miR-26a-5p | Epithelial ovarian cancer | MNDR-E-MI-33116 |
MNDR | hsa-miR-26a-5p | Nephroblastoma | MNDR-E-MI-33117 |
MNDR | hsa-miR-26a-5p | Colon cancer | MNDR-E-MI-33118 |
MNDR | hsa-miR-26a-5p | Ischemic attack transient | MNDR-E-MI-33119 |
MNDR | hsa-miR-26a-5p | Colon adenocarcinoma | MNDR-E-MI-33120 |
MNDR | hsa-miR-26a-5p | West nile virus infection | MNDR-E-MI-33121 |
MNDR | hsa-miR-26a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-33122 |
MNDR | hsa-miR-26a-5p | Familial ovarian cancer | MNDR-E-MI-33123 |
MNDR | hsa-miR-26a-5p | Prostate adenocarcinoma | MNDR-E-MI-33124 |
MNDR | hsa-miR-26a-5p | Kidney cancer | MNDR-E-MI-33125 |
MNDR | hsa-miR-26a-5p | Thyroid adenomas | MNDR-E-MI-33126 |
MNDR | hsa-miR-26a-5p | Glomerulonephritis | MNDR-E-MI-33127 |
MNDR | hsa-miR-26a-5p | Carcinoma ductal breast | MNDR-E-MI-33128 |
MNDR | hsa-miR-26a-5p | Glioblastoma | MNDR-E-MI-33129 |
MNDR | hsa-miR-26a-5p | Glioblastoma multiforme somatic | MNDR-E-MI-33130 |
MNDR | hsa-miR-26a-5p | Astrocytoma | MNDR-E-MI-33131 |
MNDR | hsa-miR-26a-5p | Glioma | MNDR-E-MI-33132 |
MNDR | hsa-miR-26a-5p | Chordoma | MNDR-E-MI-33133 |
MNDR | hsa-miR-26a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-33134 |
MNDR | hsa-miR-26a-5p | Osteosarcoma | MNDR-E-MI-33135 |
MNDR | hsa-miR-26a-5p | Inclusion body myositis | MNDR-E-MI-33136 |
MNDR | hsa-miR-26a-5p | Meningioma | MNDR-E-MI-33137 |
MNDR | hsa-miR-26a-5p | Liver cancer | MNDR-E-MI-33138 |
MNDR | hsa-miR-26a-5p | Uterus cancer | MNDR-E-MI-33139 |
MNDR | hsa-miR-26a-5p | Gastric adenocarcinoma | MNDR-E-MI-33140 |
MNDR | hsa-miR-26a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-33141 |
MNDR | hsa-miR-26a-5p | Pituitary adenoma | MNDR-E-MI-33142 |
MNDR | hsa-miR-26a-5p | Lung squamous cell carcinoma | MNDR-E-MI-33143 |
MNDR | hsa-miR-26a-5p | Lung adenocarcinoma | MNDR-E-MI-33144 |
MNDR | hsa-miR-26a-5p | Thyroid carcinoma | MNDR-E-MI-33145 |
MNDR | hsa-miR-26a-5p | Papillary thyroid carcinoma | MNDR-E-MI-33146 |
MNDR | hsa-miR-26a-5p | Bladder urothelial carcinoma | MNDR-E-MI-33147 |
MNDR | hsa-miR-26a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-33148 |
MNDR | hsa-miR-26a-5p | Carcinoma renal cell | MNDR-E-MI-33149 |
MNDR | hsa-miR-26a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-33150 |
MNDR | hsa-miR-26a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-33151 |
MNDR | hsa-miR-26a-5p | Biliary tract cancer | MNDR-E-MI-33152 |
MNDR | hsa-miR-26a-5p | Cholangiocarcinoma | MNDR-E-MI-33153 |
MNDR | hsa-miR-26a-5p | Esophageal cancer | MNDR-E-MI-33154 |
MNDR | hsa-miR-26a-5p | Liver cirrhosis | MNDR-E-MI-33155 |
MNDR | hsa-miR-26a-5p | Lung small cell carcinoma | MNDR-E-MI-33156 |
MNDR | hsa-miR-26a-5p | Encephalopathy bovine spongiform | MNDR-E-MI-33157 |
MNDR | hsa-miR-26a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-33158 |
MNDR | hsa-miR-26a-5p | Myocardial infarction | MNDR-E-MI-33159 |
MNDR | hsa-miR-26a-5p | Heart failure | MNDR-E-MI-33160 |
MNDR | hsa-miR-26a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-33161 |
MNDR | hsa-miR-26a-5p | Breast invasive carcinoma | MNDR-E-MI-33162 |
MNDR | hsa-miR-26a-5p | Hepatocellular carcinoma | MNDR-E-MI-33163 |
MNDR | hsa-miR-26a-5p | Familiar ovarian carcinoma | MNDR-E-MI-33164 |
MNDR | hsa-miR-26a-5p | B-cell lymphoma | MNDR-E-MI-33165 |
MNDR | hsa-miR-26a-5p | Rheumatoid arthritis | MNDR-E-MI-33166 |
MNDR | hsa-miR-26a-5p | T-cell leukemia | MNDR-E-MI-33167 |
MNDR | hsa-miR-26a-5p | Retinoblastoma | MNDR-E-MI-33168 |
MNDR | hsa-miR-26a-5p | Neuroblastoma | MNDR-E-MI-33169 |
MNDR | hsa-miR-26a-5p | Barrett's adenocarcinoma | MNDR-E-MI-33170 |
MNDR | hsa-miR-26a-5p | Osteoarthritis | MNDR-E-MI-33171 |
MNDR | hsa-miR-26a-5p | Hodgkin lymphoma | MNDR-E-MI-33172 |
MNDR | hsa-miR-26a-5p | Ulcerative colitis | MNDR-E-MI-33173 |
MNDR | hsa-miR-26a-5p | Burkitt lymphoma | MNDR-E-MI-33174 |
MNDR | hsa-miR-26a-5p | Tonsil cancer | MNDR-E-MI-33175 |
MNDR | hsa-miR-26a-5p | Neuromyelitis optica | MNDR-E-MI-33176 |
MNDR | hsa-miR-26a-5p | Skin cutaneous melanoma | MNDR-E-MI-33177 |
MNDR | hsa-miR-26a-5p | Skin melanoma | MNDR-E-MI-33178 |
MNDR | hsa-miR-26a-5p | Acute myelocytic leukemia | MNDR-E-MI-33179 |
MNDR | hsa-miR-26a-5p | Colorectal cancer | MNDR-E-MI-33180 |
MNDR | hsa-miR-26a-5p | Nasopharyngeal carcinoma | MNDR-E-MI-33181 |
MNDR | hsa-miR-26a-5p | Nasopharynx carcinoma | MNDR-E-MI-33182 |
MNDR | hsa-miR-26a-5p | Leukemia lymphoblastic acute | MNDR-E-MI-33183 |
MNDR | hsa-miR-26a-5p | Ovarian epithelial cancer | MNDR-E-MI-33184 |
MNDR | hsa-miR-26a-5p | Diabetic nephropathies | MNDR-E-MI-33185 |
MNDR | hsa-miR-26a-5p | Ependymoma | MNDR-E-MI-33186 |
MNDR | hsa-miR-26a-5p | Cardiac hypertrophy | MNDR-E-MI-33187 |
MNDR | hsa-miR-26a-5p | Hyperalgesia | MNDR-E-MI-33188 |
MNDR | hsa-miR-26a-5p | Nasopharyngeal cancer | MNDR-E-MI-33189 |
MNDR | hsa-miR-26a-5p | Prostatic neoplasms | MNDR-E-MI-33190 |
MNDR | hsa-miR-26a-5p | Sleep deprivation | MNDR-E-MI-33191 |
MNDR | hsa-miR-26a-5p | Epstein-barr virus infections | MNDR-E-MI-33192 |
MNDR | hsa-miR-26a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-33193 |
MNDR | hsa-miR-26a-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-33194 |
MNDR | hsa-miR-26a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-33195 |
MNDR | hsa-miR-26a-5p | Chronic pain | MNDR-E-MI-33196 |
MNDR | hsa-miR-26a-5p | Stroke lacunar | MNDR-E-MI-33197 |
MNDR | hsa-miR-26a-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-33198 |
MNDR | hsa-miR-26a-5p | Barrett's carcinogenesis | MNDR-E-MI-33199 |
MNDR | hsa-miR-26a-5p | Breast cancer her3+ negative | MNDR-E-MI-33200 |
MNDR | hsa-miR-26a-5p | Duke C | MNDR-E-MI-33201 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA1 | Homo sapiens | RR00022107 |
TOP